This is a summary of the European public assessment report (EPAR) for Nulojix. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nulojix.
Therapeutic Indication
### Therapeutic indication Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
Therapeutic Area (MeSH)
ATC Code
L04AA28
ATC Item
belatacept
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| belatacept | N/A | Belatacept |
EMA Name
Nulojix
Medicine Name
Nulojix
Aliases
N/A
